Tirzepatide cost: what Zepbound and Mounjaro really cost each month

The sticker price of tirzepatide and the price most people pay are two different numbers. Lilly’s list price runs up to $1,086.37 a month for Zepbound and $1,112.16 for Mounjaro, while the same company sells Zepbound vials and KwikPens to cash-paying patients for $299 to $449. People with commercial coverage may pay $25. Which number applies depends on your insurance, the brand on the prescription and the device.

What tirzepatide costs, by route

What does tirzepatide cost per year?

At the $449 refill price, a full year on a higher dose comes to about $5,837, because a Lilly “month” is 28 days and a year holds 13 fills. Someone who moves up the label’s ladder at the fastest pace pays a little less in the first year: one fill at $299, one at $399 and eleven at $449, or about $5,637. Lose the refill price on 10 mg or higher and the same 13 fills reach $9,087. Taxes and needles or syringes are extra.

List price: the number almost nobody pays

List price, also called wholesale acquisition cost, is what Lilly charges wholesalers. Lilly gives Zepbound’s list price as a range, $499 to $1,086.37 per fill, and Mounjaro’s as $1,112.16 per fill, where a fill is four pens. Both figures date from January 1, 2026, and Lilly’s pages still showed them on November 2.

If you fill a pen at a retail pharmacy with no insurance and no card, you pay something close to list plus the pharmacy’s margin. Every other row in the table exists to avoid that.

Self-pay: the real cash price for Zepbound

In August 2024, Lilly started selling Zepbound 2.5 mg and 5 mg vials directly to patients at $399 and $549 a month, roughly half the list price of the pens. Lilly’s December 1, 2025 announcement set today’s tiers. All six strengths now come as vials and KwikPens, at the same self-pay price for each strength.

The condition on the $449 tier matters. It applies to your first fill and to refills completed within 45 days of your last delivery. Miss that window and 7.5 mg reverts to $499, and 10, 12.5 and 15 mg revert to $699. The 2.5 mg and 5 mg prices stay the same. Since a Lilly month is 28 days, that leaves 17 days of slack on each refill.

Some details are easy to miss:

• Vials are self-pay only and available only through LillyDirect. They cannot be billed to insurance.
• The KwikPen holds four weekly doses. It takes a new pen needle each week. Lilly also lists it with select insurance.
• 2.5 mg lasts only about a month. The label says it is a starting dose and not approved for maintenance, so the $299 price is not a long-term one.
• HSA and FSA funds may be eligible, depending on your plan.
• Delivery or pickup is free through LillyDirect, with pickup at Walmart Pharmacy for vials and KwikPens.

A vial still needs a syringe. The dose on a Lilly vial is a fixed volume, so there is no units math, and where to inject Zepbound compares the devices.

Mounjaro has a self-pay route too, at $499 a month at every dose for its single-dose pens. Lilly’s pricing page describes self-pay options for people whose commercial or government insurance does not cover it, or who have no insurance.

Savings cards for commercially insured people

Lilly’s savings cards are for commercial insurance only, and the current terms on both cards end December 31, 2026. As of November 2, Lilly’s pages still showed that date with no 2027 terms, so it is worth checking before January.

Anyone on Medicare, Medicaid, TRICARE, the VA or a state assistance program is ineligible. Plans using what Lilly calls an alternate funding program are excluded too. The Zepbound card covers the single-dose pen and KwikPen, not vials, and it cannot be combined with other discounts. Coverage can also change: Lilly reports that Zepbound coverage was restored on select CVS Caremark formularies, so it is worth rechecking if you were dropped.

Why does insurance say no?

Coverage for the two brands diverges because of what each is approved for. Mounjaro is a diabetes drug, and diabetes drugs are a standard formulary category, so plans commonly cover it, usually with prior authorization. Zepbound is a weight-management drug, and many employer plans exclude that category entirely. Plans that do cover it typically require a documented BMI, prior lifestyle attempts and sometimes step therapy.

Two practical points follow. The brand on the prescription sets the rules, even though the drug is the same. And if your plan excludes Zepbound, the card’s $499 pen price is usually worse than the $299 to $449 self-pay price, so uninsured and excluded patients often land in the same place.

Lilly’s coverage checker gives an estimate, and your insurer has the final word. Medicaid, VA, TRICARE and other government programs have their own rules. Mounjaro’s August 28, 2026 cardiovascular indication applies to adults with type 2 diabetes at high risk, and it does not extend to Zepbound, so it gives no new coverage argument for weight management.

Medicare: what is covered and what is not

Medicare Part D’s statute excludes “agents when used for weight loss.” CMS’s November 2024 fact sheet said anti-obesity drugs are “only coverable in Part D if the drug is being used to treat another condition,” and a proposal to reinterpret that was left out of the April 2025 final rule. That leaves three routes:

• Mounjaro for type 2 diabetes is covered the way any diabetes drug is.
• Zepbound for moderate-to-severe sleep apnea with obesity is a medical use. Lilly says that prescription can go to your Part D plan. It does not qualify for the Bridge.
• The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027. It covers the Zepbound KwikPen for weight management at no more than $50 for a 28-day supply. Lilly says the single-dose pen and vial are not included, so the prescription must be written for the KwikPen.

To qualify, Lilly’s page says you need Part D coverage on an eligible plan type, a prescription for weight management, and a BMI of 35 or higher, or 27 or higher with certain weight-related conditions. People already on a GLP-1 can qualify if their BMI was in range when they started. A prior authorization is needed for the first fill, and coverage is not guaranteed. All sales through the program are final.

Legitimate ways to pay less

• Check your coverage first, since a covered pen at $25 beats any cash price.
• Refill inside 45 days. On 10 mg or higher, that one habit is worth $250 a month.
• Ask which device fits your coverage. Medicare’s Bridge is KwikPen-only, vials are self-pay only, and the $25 Zepbound card is for the single-dose pen.
• Use HSA or FSA funds if your plan allows it.
• Make sure the brand matches your diagnosis. Type 2 diabetes usually points to Mounjaro coverage, and sleep apnea can open a route for Zepbound.
• Raise cost with your prescriber. The price steps by dose, and the tirzepatide dosage chart shows which doses are maintenance options. The dose itself is a clinical decision.

The cheapest GLP-1 without insurance guide compares tirzepatide with other drugs.

What to avoid

• Compounded products chosen on price alone. Each pharmacy or telehealth program sets its own price, and advertised monthly figures commonly leave out membership, visit and shipping fees. Ask for the most you would pay in any single month, then compare it with Lilly’s price. The FDA does not review these products, and it has more than 730 adverse event reports tied to compounded tirzepatide as of May 31, 2026. Since early 2025 they have been lawful only in narrow cases, covered in the compounded tirzepatide guide.
• Prices that seem too good to be true. The FDA lists this as a red flag, along with no screening or prescription requirement.
• “Research use” products. These are not legal to use on people, whatever the price.
• Letting a refill lapse by accident. It is the most avoidable cost on this page.

Prices here were checked on Lilly’s pages on November 2, 2026, and Lilly can change its terms without notice. The prescriber sets the dose; this page only reports what each route costs.